**Summary of Avingtrans PLC Preliminary Results for the Year Ended 31 May 2025**
Avingtrans PLC, a designer and manufacturer of critical components and systems for the energy, medical, and industrial sectors, reported strong preliminary results for the year ended 31 May 2025. Key highlights include
### **Financial Performance**
**Revenue Growth**Revenue from continuing operations increased by 14.5% to £156.4 million, driven by strong performance in the Energy (AES) division.
**Gross Margin**Stable at 31.7% (2024: 32.2%).
**Adjusted EBITDA**Slightly ahead of market expectations at £16.7 million (2024: £14.0 million), with AES contributing £21.5 million.
**Adjusted PBT**£8.6 million (2024: £7.3 million), reflecting strong growth in AES and lower restructuring costs.
**Adjusted Diluted EPS**23.7p (2024: 18.5p).
**Net Debt**Increased to £12.3 million (2024: £6.1 million), ahead of market expectations.
**Dividend**Proposed final dividend of 3.0p per share, totaling 4.9p for the year (2024: 4.7p).
### **Operational Highlights**
**Energy (AES)**Revenue grew by 13.9% to £151.5 million, with adjusted EBITDA up 20% to £21.5 million. Strong performance was driven by Hayward Tyler, Ormandy, and Booth Industries, benefiting from global trends in AI, data centers, and new nuclear power.
**Medical (MII)**Revenue increased to £4.9 million (2024: £3.7 million), with LBITDA of £3.6 million (2024: £2.8 million). Adaptix and Magnetica made progress in commercialization, with Adaptix winning the "Innovation of the Year" award for its NDT product.
### **Strategic Progress**
**AES Division**Strengthened nuclear installed base and expanded into defense and critical national infrastructure. Secured significant contracts, including a $16 million order from Korea Hydro & Nuclear Power (KHNP).
**MII Division**Advanced development of compact helium-free MRI systems and 3D X-ray systems, with Adaptix expanding its distribution channels and Magnetica progressing towards FDA approval.
### **Outlook**
**Current Trading**Performance in line with management expectations, with strong momentum continuing into FY26, supported by contract wins in AES.
**Strategic Direction**Confident about future opportunities across AES and MII, with a focus on acquisitions to enhance shareholder value while maintaining a conservative approach to debt.
### **Chairman’s Statement**
Chairman Roger McDowell highlighted the robust performance in challenging global markets, exceeding market expectations. The company’s PIE (Pinpoint-Invest-Exit) strategy was successfully deployed, with investments in Slack and Parr, Adaptix, and Magnetica. The AES division delivered record results, while MII made significant progress in medical imaging technologies. The Board remains optimistic about future growth and shareholder value creation.
### **ESG and Sustainability**
Established an ESG Committee to focus on operational eco-efficiency and development of new technologies.
Progress in reducing carbon intensity and integrating sustainability into core business activities.
### **Conclusion**
Avingtrans PLC demonstrated strong financial and operational performance, driven by its AES division and strategic investments in MII. The company is well-positioned for future growth, with a healthy order book and a focus on sustainable value creation.